非アルコール性脂肪肝炎(NASH)治療薬の世界市場2016-2020

◆英語タイトル:Global Non-alcoholic Steatohepatitis Market 2016-2020
◆商品コード:IRTNTR8374
◆発行会社(調査会社):Technavio
◆発行日:2016年5月6日
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、非アルコール性脂肪肝炎(NASH)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、非アルコール性脂肪肝炎(NASH)治療薬の世界市場規模及び予測、剤形別分析、投与経路(ROA)別分析、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Non-Alcoholic Steatohepatitis (NASH)
NAFL disease, also known as fatty infiltration, is characterized by the accumulation of fat in the liver. It is of two types: NAFL and NASH. Fatty inflammation characterized by higher fat deposition than the normal level, 5%-10%, causes the disease. NASH causes severe inflammation of the liver, leading to damage of the organ. It is a benign condition of unknown etiology and is asymptomatic in nature during its initial stages, resulting in late diagnosis. Conditions such as obesity, diabetes, hyperlipidemia, insulin resistance, and toxicity by drugs such as amiodarone, tamoxifen, and perhexiline maleate can cause NASH.

Technavio’s analysts forecast the global NASH market to grow at a CAGR of 24.58% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global NASH market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of off-label drugs, originally indicated for the treatment of diabetes, obesity, and associated conditions.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global NASH Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Arena Pharmaceuticals
• AstraZeneca
• F Hoffmann-La Roche
• GSK
• Novo Nordisk
• Vivus

[Other prominent vendors]
• Arisaph Pharmaceuticals
• Cempra Pharmaceuticals
• Galectin Therapeutics
• Galmed Pharmaceuticals
• Genfit
• Gilead
• Immuron
• Interceptpharma
• Raptor Pharmaceutical
• Shire
• Tobira Therapeutics
• Verva
• Viking Therapeutics

[Market driver]
• Increase in sedentary lifestyle
• For a full, detailed list, view our report

[Market challenge]
• Limited understanding of disease pathophysiology
• For a full, detailed list, view our report

[Market trend]
• Patient assistance programs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Symptoms and signs
• Pathophysiology
• Risk factors
• Diagnosis
• Treatment
• Epidemiology
• Economic burden

PART 06: Pipeline analysis
• Pipeline information of NASH
• Clinical trials for NASH

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by dosage form
• Solid
• Liquid

PART 09: Market segmentation by route of administration
• Oral
• Parenteral

PART 10: Geographical segmentation
• Global NASH drugs market by geographical segmentation 2015-2020
• NASH drugs market in Americas
• NASH drugs market in US
• NASH drugs market in EMEA
• NASH drugs market in APAC

PART 11: Market drivers
• Increase in sedentary lifestyle
• Prevalence of associated health conditions
• Promising pipeline
• Significant unmet medical needs

PART 12: Impact of drivers

PART 13: Market challenges
• Limited understanding of disease pathophysiology
• Insufficient diagnostic technology for NASH
• Stringent regulatory procedure
• Adverse effects of drugs

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Rise in public awareness
• Increase in strategic alliances
• Patient assistance programs
• Usage of off-label drugs

PART 16: Vendor landscape
• Competitive scenario
• Arena Pharmaceuticals
• AstraZeneca
• F Hoffmann-La Roche
• GSK
• Novo Nordisk
• Vivus
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Conditions associated with NASH
Exhibit 03: Diagnosis of NASH
Exhibit 04: Global NASH drugs market: Pipeline portfolio
Exhibit 05: Clinical trials for NASH by development phase
Exhibit 06: Clinical trials for NASH by trial status
Exhibit 07: Global NASH drugs market 2015-2020 ($ millions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global NASH drugs market by dosage form
Exhibit 10: Segmentation of global NASH drugs market by route of administration
Exhibit 11: Global NASH drugs market by geographical segmentation 2015
Exhibit 12: Global NASH drugs market revenue by geography 2015-2020 ($ millions)
Exhibit 13: NASH drugs market in Americas 2015-2020 ($ millions)
Exhibit 14: NASH market in US 2015-2020 ($ millions)
Exhibit 15: NASH drugs market in EMEA 2015-2020 ($ millions)
Exhibit 16: NASH drugs market in APAC 2015-2020 ($ millions)
Exhibit 17: Impact of drivers
Exhibit 18: Impact of drivers and challenges
Exhibit 19: Arena Pharmaceuticals: YoY revenue of Belviq 2013-2014 ($ millions)
Exhibit 20: Arena Pharmaceuticals: Key takeaways
Exhibit 21: AstraZeneca: Cardiovascular and metabolic diseases segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 22: Top selling products in 2014 ($ millions)
Exhibit 23: AstraZeneca: YoY growth and revenue of Bydureon 2012-2014 ($ millions)
Exhibit 24: AstraZeneca: YoY growth and revenue of Byetta 2012-2014 ($ millions)
Exhibit 25: AstraZeneca: YoY growth and revenue of Onglyza/ Komboglyze/ Komboglyze XR 2012-2014 ($ millions)
Exhibit 26: AstraZeneca: Key takeaways
Exhibit 27: Roche: Key takeaways
Exhibit 28: GSK: Key takeaways
Exhibit 29: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 30: Novo Nordisk: R&D expenditure 2014
Exhibit 31: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2012-2014 ($ millions)
Exhibit 32: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2012-2014 ($ millions)
Exhibit 33: Novo Nordisk: YoY growth and revenue of Prandin 2012-2014 ($ millions)
Exhibit 34: Novo Nordisk: Key takeaways
Exhibit 35: Vivus: YoY growth and revenue of Qsymia 2012-2014 ($ millions)
Exhibit 36: Vivus: Key takeaways



【掲載企業】

Arena Pharmaceuticals, AstraZeneca, F Hoffmann-La Roche, GSK, Novo Nordisk, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Immuron, Interceptpharma, Raptor Pharmaceutical, Shire, Tobira Therapeutics, Verva, Viking Therapeutics.


【レポートのキーワード】

非アルコール性脂肪肝炎(NASH)、非アルコール性脂肪肝炎治療薬、医薬品、肥満、糖尿病

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[非アルコール性脂肪肝炎(NASH)治療薬の世界市場2016-2020]販売に関する免責事項
★調査レポート[非アルコール性脂肪肝炎(NASH)治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆